Introduction
Interleukin 6 (Il 6) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
flowchart TD
entities_interleukin_6["Interleukin-6 IL-6"]
entities_interleukin_6_1["Introduction"]
entities_interleukin_6 -->|"related to"| entities_interleukin_6_1
style entities_interleukin_6_1 fill:#81c784,stroke:#333,color:#000
entities_interleukin_6_2["important"]
entities_interleukin_6 -->|"related to"| entities_interleukin_6_2
style entities_interleukin_6_2 fill:#81c784,stroke:#333,color:#000
entities_interleukin_6_3["component"]
entities_interleukin_6 -->|"related to"| entities_interleukin_6_3
style entities_interleukin_6_3 fill:#81c784,stroke:#333,color:#000
entities_interleukin_6_4["neurobiology"]
entities_interleukin_6 -->|"related to"| entities_interleukin_6_4
style entities_interleukin_6_4 fill:#81c784,stroke:#333,color:#000
style entities_interleukin_6 fill:#4fc3f7,stroke:#333,color:#000
...Introduction
Interleukin 6 (Il 6) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
Interleukin-6 (IL-6) is a pleiotropic cytokine with critical roles in immune regulation, inflammation, and neuronal survival. IL-6 is implicated in the pathogenesis of multiple neurodegenerative diseases and is a target for therapeutic intervention["@erta2012"]. In the central nervous system, IL-6 is produced by astrocytes, [microglia](/cell-types/microglia-neuroinflammation), and neurons, and acts through the IL-6 receptor (IL-6R) and gp130 signal-transducing subunit["@rothaug2016"]. [@rothaug2016]
Biology of IL-6
Structure and Receptors
IL-6 is a 21-28 kDa glycoprotein cytokine that signals through two distinct mechanisms: [@swardfager2010]
- Classical signaling: IL-6 binds to membrane-bound IL-6Rα, then recruits gp130
- Trans-signaling: IL-6 binds to soluble IL-6R (sIL-6R), enabling cells that only express gp130 to respond
IL-6 Signaling Pathways
Upon binding to IL-6R/gp130 complexes: [@qin2016]
- JAK/STAT pathway: STAT3 activation and nuclear translocation
- MAPK pathway: Ras-Raf-MEK-ERK cascade
- PI3K/Akt pathway: Cell survival signaling
The balance between classical and trans-signaling determines the biological outcome, with trans-signaling often pro-inflammatory. [@sims2010]
Production in the CNS
In the central nervous system, IL-6 is produced by various cell types: [@mitchell2019]
- [Astrocytes](/entities/astrocytes): Major producers under resting and activated conditions
- [Microglia](/cell-types/microglia): Rapid responders to injury and infection
- [Neurons](/entities/neurons): Produce IL-6 in response to excitotoxicity
- Oligodendrocytes: Contribute to demyelinating conditions
Role in Neurodegeneration
Alzheimer's Disease
IL-6 is elevated in the brains, CSF, and blood of Alzheimer's disease patients[@swardfager2010]: [@korn2017]
- Promotes [amyloid-beta](/proteins/amyloid-beta) production and aggregation
- Contributes to [tau](/proteins/tau) pathology through kinase activation
- Drives chronic neuroinflammation
- Associated with disease severity and progression
The
[amyloid-beta](/proteins/amyloid-beta)-IL-6 axis represents a key pathway in AD pathogenesis, where amyloid plaques stimulate IL-6 production, which in turn enhances amyloid processing.
Parkinson's Disease
Elevated IL-6 is found in the substantia nigra, striatum, and CSF of PD patients[@qin2016]:
- Contributes to dopaminergic neuron vulnerability
- Activates microglia and astrocytes
- Linked to disease duration and severity
IL-6 polymorphisms have been associated with increased PD risk, suggesting a genetic component to IL-6-mediated neurodegeneration.
Stroke and Ischemia
IL-6 has both detrimental and protective roles in cerebral ischemia[@sims2010]:
- Acute elevation contributes to excitotoxic damage
- IL-6 has neuroprotective properties through STAT3 activation
- Post-stroke IL-6 levels predict outcomes
The timing of IL-6 modulation may determine whether its effects are beneficial or harmful.
Amyotrophic Lateral Sclerosis (ALS)
Elevated IL-6 in CSF and serum correlates with progression in ALS patients[@mitchell2019]:
- Contributes to motor neuron injury
- Activates glial cells
- Associated with faster disease progression
Multiple Sclerosis (MS)
IL-6 promotes Th17 differentiation and demyelination in MS[@korn2017]:
- Drives autoimmune responses
- Impairs [blood-brain barrier](/entities/blood-brain-barrier) integrity
- Therapeutic targeting shows promise
Huntington's Disease
Increased IL-6 is found in the striatum and [cortex](/brain-regions/cortex) of HD patients:
- Contributes to medium spiny neuron dysfunction
- Associated with CAG repeat length
- Potential biomarker for disease progression
Therapeutic Targeting
IL-6 Receptor Antibodies
Therapeutic strategies targeting IL-6 include:
Tocilizumab: Humanized anti-IL-6R antibody, FDA-approved for rheumatoid arthritis
Sarilumab: Fully human anti-IL-6R antibody
Siltuximab: Chimeric anti-IL-6 antibody
Satralizumab: Aquaporin-4 antibody for NMOSDClinical Considerations
- CNS penetration: Limited, but peripheral effects may modulate neuroinflammation
- Clinical trials: Ongoing for Alzheimer's, Parkinson's, and ALS
- Biomarker potential: IL-6 as a biomarker for disease progression
- Genetic studies: IL-6 polymorphisms linked to neurodegeneration risk
Alternative Approaches
- JAK inhibitors: Block downstream signaling
- STAT3 inhibitors: Target nuclear translocation
- Soluble gp130: Neutralize trans-signaling
Research Methods
Detection Techniques
- ELISA: Quantify IL-6 in CSF and serum
- Immunohistochemistry: Localize IL-6 in brain tissue
- qPCR: Measure IL-6 mRNA expression
- Multiplex assays: Profile multiple cytokines simultaneously
Animal Models
- IL-6 transgenic mice: Overexpress IL-6 in CNS
- IL-6 knockout mice: Study loss-of-function
- AAV-mediated delivery: Targeted CNS expression
Future Research Directions
Current research focuses on understanding the dual nature of IL-6 signaling in the CNS. Selective targeting of trans-signaling while preserving classical signaling represents a promising therapeutic approach. Biomarker studies are evaluating IL-6 levels for disease diagnosis and treatment response prediction.
Key research priorities include:
- Developing CNS-penetrant IL-6 inhibitors
- Identifying patient subgroups who may benefit most from treatment
- Understanding IL-6 interactions with other cytokines
- Exploring IL-6 as a biomarker for clinical trials
See Also
- [Microglia](/entities/microglia)
- [Neuroinflammation](/mechanisms/microglia-neuroinflammation)
- [JAK/STAT Signaling](/mechanisms/jak-stat-signaling-pathway-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Cytokines](/dock3---dedicator-of-cytokinesis-3)
External Links
- [IL-6 Wikipedia](https://en.wikipedia.org/wiki/Interleukin-6)
- [Cytokines and Inflammation (NIAID)](https://www.niaid.nih.gov/research/cytokines-inflammation)
- [Neuroinflammation Research (Nature)](https://www.nature.com/subjects/neuroinflammation)
Background
The study of Interleukin 6 (Il 6) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Brain Atlas Resources
- [Allen Human Brain Atlas - IL6 Expression](https://human.brain-map.org/microarray/search/show?search_term=IL6): Gene expression data in human brain
- [Allen Mouse Brain Atlas - IL6](https://mouse.brain-map.org/search?type=gene&term=IL6): Mouse brain expression patterns
- [BrainSpan - Developmental Transcriptome](https://brainspan.org/static/download.html): Developmental expression data
References
[Erta M, Quintana A, Hidalgo J, Interleukin-6, a major cytokine in the central nervous system (2012)](https://doi.org/10.7150/ijbs.5099)
[Rothaug M, Becker-Pauly C, Rose-John S, The role of interleukin-6 signaling in neurological disorders (2016)](https://doi.org/10.1186/s40478-016-0376-5)
[Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N, A meta-analysis of cytokines in Alzheimer's disease (2010)](https://doi.org/10.1016/j.biopsych.2010.06.012)
[Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y, Aberrations in peripheral inflammatory cytokine levels in Parkinson's disease: a systematic review and meta-analysis (2016)](https://doi.org/10.3389/fimmu.2016.00274)
[Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ, IL-6 in CNS autoimmunity (2010)](https://doi.org/10.1007/978-1-4419-5912-3_4)
[Mitchell KM, Doty RL, Ilmarinen T, et al, IL-6 and disease progression in amyotrophic lateral sclerosis (2019)](https://doi.org/10.1212/WNL.0000000000007939)
[Korn T, Kallies A, IL-6 and its receptor in autoimmunity (2017)](https://doi.org/10.1038/nri.2017.22)Pathway Diagram
The following diagram shows the key molecular relationships involving Interleukin-6 (IL-6) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)